Related Experiment Video

Updated: Jul 2, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents

Eriko Simamura1, Hiroki Shimada, Toshihisa Hatta

  • 1Department of Molecular and Cell Structural Science, Kanazawa Medical University, Ishikawa, Uchinada, Japan. simamura@kanazawa-med.ac.jp

Journal of Bioenergetics and Biomembranes
|August 16, 2008
PubMed

Insights

Voltage-dependent anion channels (VDACs) are promising anti-cancer drug targets. Targeting VDAC1 and VDAC2 shows potential for selective cancer cell death induction and novel therapeutic strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Mitochondrial voltage-dependent anion channels (VDACs) are increasingly recognized as key regulators in cancer cell metabolism and survival.
  • Overexpression of VDAC isoforms (VDAC1-3) is observed in various cancer types, suggesting their potential as selective therapeutic targets.
  • Current anti-cancer agents are being developed to target VDACs for enhanced efficacy and reduced toxicity.

Purpose of the Study:

  • To review the role of VDACs as pharmacological targets in cancer therapy.
  • To explore the mechanisms by which VDAC-targeting agents induce cancer cell death.
  • To highlight the potential of VDACs for developing novel anti-cancer drugs.

Main Methods:

  • Review of existing literature on VDACs in cancer biology and drug development.
  • Analysis of studies investigating VDAC1- and VDAC2-mediated cell death pathways.
  • Examination of the relationship between VDAC expression, cancer metabolism, and therapeutic response.

Main Results:

  • Furanonaphthoquinones (FNQs) induce apoptosis via VDAC1 by promoting NADH-dependent reactive oxygen species (ROS) production.
  • Erastin triggers non-apoptotic cell death through VDAC2, activating the RAS-RAF-MEK pathway.
  • VDACs facilitate ATP transport to highly expressed hexokinase (HK) in cancer cells, potentially driving VDAC up-regulation through high glycolysis.

Conclusions:

  • VDACs represent novel and promising pharmacological targets for anti-cancer drug development.
  • Targeting specific VDAC isoforms offers potential for selective cancer cell killing.
  • Further research into VDAC-mediated pathways could lead to innovative cancer treatment strategies.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...